ATE528405T1 - Auf dem virus der infektiösen pferdeanämie (eiav) basierende vektoren - Google Patents
Auf dem virus der infektiösen pferdeanämie (eiav) basierende vektorenInfo
- Publication number
- ATE528405T1 ATE528405T1 AT07015653T AT07015653T ATE528405T1 AT E528405 T1 ATE528405 T1 AT E528405T1 AT 07015653 T AT07015653 T AT 07015653T AT 07015653 T AT07015653 T AT 07015653T AT E528405 T1 ATE528405 T1 AT E528405T1
- Authority
- AT
- Austria
- Prior art keywords
- eiav
- based vectors
- anemia virus
- equine infectious
- infectious anemia
- Prior art date
Links
- 239000013598 vector Substances 0.000 title abstract 2
- 241000713730 Equine infectious anemia virus Species 0.000 title 2
- 239000002773 nucleotide Substances 0.000 abstract 2
- 125000003729 nucleotide group Chemical group 0.000 abstract 2
- 108091026890 Coding region Proteins 0.000 abstract 1
- 241000713666 Lentivirus Species 0.000 abstract 1
- 241000288906 Primates Species 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 108700004026 gag Genes Proteins 0.000 abstract 1
- 101150098622 gag gene Proteins 0.000 abstract 1
- 230000001177 retroviral effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15051—Methods of production or purification of viral material
- C12N2740/15052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15061—Methods of inactivation or attenuation
- C12N2740/15062—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
- C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9727135.7A GB9727135D0 (en) | 1997-12-22 | 1997-12-22 | Non-primate lentiviral vectors |
| GBGB9811037.2A GB9811037D0 (en) | 1998-05-22 | 1998-05-22 | Proretoviral vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE528405T1 true ATE528405T1 (de) | 2011-10-15 |
Family
ID=26312829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07015653T ATE528405T1 (de) | 1997-12-22 | 1998-12-22 | Auf dem virus der infektiösen pferdeanämie (eiav) basierende vektoren |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US6312683B1 (de) |
| EP (2) | EP1895010B1 (de) |
| JP (1) | JP4578678B2 (de) |
| CN (1) | CN1322137C (de) |
| AT (1) | ATE528405T1 (de) |
| AU (1) | AU760287B2 (de) |
| CA (1) | CA2315269A1 (de) |
| CY (1) | CY1112196T1 (de) |
| DK (1) | DK1895010T3 (de) |
| ES (1) | ES2373406T3 (de) |
| PT (1) | PT1895010E (de) |
| WO (1) | WO1999032646A1 (de) |
Families Citing this family (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070213290A1 (en) * | 1996-10-17 | 2007-09-13 | Kingsman Alan J | Neurite regeneration |
| US20040266715A1 (en) * | 1999-03-31 | 2004-12-30 | Wong Liang Fong | Neurite regeneration |
| WO2001075135A1 (en) * | 2000-03-30 | 2001-10-11 | Oxford Biomedica (Uk) Limited | Retinoic acid receptor beta-2, its antagonists, and gene therapy vectors for the treatment of neurological disorders |
| ATE528405T1 (de) * | 1997-12-22 | 2011-10-15 | Oxford Biomedica Ltd | Auf dem virus der infektiösen pferdeanämie (eiav) basierende vektoren |
| GB9803351D0 (en) | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
| WO2001066150A2 (en) * | 2000-03-07 | 2001-09-13 | St. Jude Children's Research Hospital | Highly efficient gene transfer into human repopulating stem cel ls by rd114 pseudotyped retroviral vector particles |
| US6849454B2 (en) | 2000-03-07 | 2005-02-01 | St. Jude Children's Research Hospital | Highly efficient gene transfer into human repopulating stem cells by RD114 pseudotyped retroviral vector particles |
| GB0009760D0 (en) | 2000-04-19 | 2000-06-07 | Oxford Biomedica Ltd | Method |
| US6585978B1 (en) * | 2000-09-09 | 2003-07-01 | Akzo Nobel | EIA vaccine and diagnostic |
| WO2002020049A2 (en) * | 2000-09-09 | 2002-03-14 | Akzo Nobel N.V. | Eiav chimeric vaccine and diagnostic |
| US6461616B1 (en) * | 2000-09-09 | 2002-10-08 | Akzo Nobel Nv | EIAV p26 deletion vaccine and diagnostic |
| US20040018211A1 (en) * | 2002-06-26 | 2004-01-29 | Ronald Montelaro | EIA vaccine and diagnostic |
| IL154777A0 (en) * | 2000-09-14 | 2003-10-31 | Applied Research Systems | Il-6 receptor/il-6 chimera in huntington's disease |
| GB0024550D0 (de) | 2000-10-06 | 2000-11-22 | Oxford Biomedica Ltd | |
| WO2002034929A2 (en) * | 2000-10-20 | 2002-05-02 | Whitehead Institute For Biomedical Research | Expression vectors and uses thereof |
| US7575924B2 (en) | 2000-11-13 | 2009-08-18 | Research Development Foundation | Methods and compositions relating to improved lentiviral vectors and their applications |
| US6712612B1 (en) | 2000-12-12 | 2004-03-30 | Genecure Llc | Safe and stable retroviral helper cell line and related compositions and methods |
| CA2344208A1 (en) | 2001-04-30 | 2002-10-30 | Oxford Biomedica (Uk) Limited | Method |
| WO2003012054A2 (en) * | 2001-08-02 | 2003-02-13 | Institut Clayton De La Recherche | Methods and compositions relating to improved lentiviral vector production systems |
| WO2003029274A2 (en) * | 2001-09-28 | 2003-04-10 | University Of North Carolina At Chapel Hill | Paramyxoviruses as gene transfer vectors to lung cells |
| CA2462628C (en) | 2001-10-02 | 2019-08-20 | Institut Clayton De La Recherche | Restricted expression lentiviral vectors |
| US20030121062A1 (en) * | 2001-12-21 | 2003-06-26 | Oxford Biomedica (Uk) Limited | Transgenic organism |
| JP2005512598A (ja) * | 2001-12-21 | 2005-05-12 | オックスフォード バイオメディカ （ユーケー） リミテッド | Ｅｉａｖなどのレンチウイルス発現ベクターを使用するトランスジェニック生物の作製方法 |
| US9738907B2 (en) | 2002-02-01 | 2017-08-22 | Oxford Biomedica (Uk) Limited | Viral vector |
| DK1504108T3 (da) | 2002-02-01 | 2013-06-10 | Oxford Biomedica Ltd | Lentivirusvektor |
| GB0215287D0 (en) * | 2002-07-02 | 2002-08-14 | Oxford Biomedica Ltd | 5T4 antigen expression |
| US7662625B2 (en) * | 2002-07-02 | 2010-02-16 | Cancer Research Technology Limited | Methods for detecting the differentiation status of cells using 5T4 antigen expression |
| WO2004022761A1 (en) * | 2002-09-03 | 2004-03-18 | Oxford Biomedica (Uk) Limited | Retroviral vector and stable packaging cell lines |
| GB0220467D0 (en) | 2002-09-03 | 2002-10-09 | Oxford Biomedica Ltd | Composition |
| WO2004022722A2 (en) * | 2002-09-06 | 2004-03-18 | Massachusetts Institute Of Technology | Lentiviral vectors, related reagents, and methods of use thereof |
| DK1563069T3 (da) * | 2002-11-22 | 2012-07-23 | Inst Clayton De La Rech | Sammensætninger og systemer til genregulering |
| EP2390352A1 (de) | 2003-03-18 | 2011-11-30 | Quantum Genetics Ireland Limited | Systeme und Methoden zur Erhöhung der Milchproduktion bei Tieren |
| US7468273B2 (en) | 2003-05-01 | 2008-12-23 | Meial Limited | Canine GHRH gene, polypeptides and methods of use |
| WO2005047458A2 (en) | 2003-06-18 | 2005-05-26 | Genelux Corporation | Modified recombinant vaccina viruses and other microorganisms, uses thereof |
| US20050214316A1 (en) | 2003-11-13 | 2005-09-29 | Brown Thomas P | Methods of characterizing infectious bursal disease virus |
| EP1718770B1 (de) | 2004-02-19 | 2011-05-25 | The Governors of the University of Alberta | Leptinpromotor-polymorphismen und verwendungen davon |
| FR2870126B1 (fr) | 2004-05-17 | 2009-07-17 | Pasteur Institut | Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin |
| US20060233757A1 (en) * | 2004-08-27 | 2006-10-19 | Wendy Maury | Vectors with viral insulators |
| RS51324B (sr) | 2005-04-25 | 2010-12-31 | Merial Ltd. | Vakcine protiv nipah virusa |
| US20080241184A1 (en) | 2005-08-25 | 2008-10-02 | Jules Maarten Minke | Canine influenza vaccines |
| US7771995B2 (en) | 2005-11-14 | 2010-08-10 | Merial Limited | Plasmid encoding human BMP-7 |
| CA2629522A1 (en) | 2005-11-14 | 2007-05-18 | Merial Limited | Gene therapy for renal failure |
| US7862821B2 (en) | 2006-06-01 | 2011-01-04 | Merial Limited | Recombinant vaccine against bluetongue virus |
| WO2008100292A2 (en) | 2006-10-16 | 2008-08-21 | Genelux Corporation | Modified vaccinia virus strains for use in diagnostic and therapeutic methods |
| GB0702695D0 (en) * | 2007-02-12 | 2007-03-21 | Ark Therapeutics Ltd | Production of vectors |
| CN101705246B (zh) * | 2007-04-29 | 2012-06-27 | 中国农业科学院哈尔滨兽医研究所 | 慢病毒基因转移载体、其制备方法和应用 |
| EP2209889B1 (de) | 2007-11-16 | 2016-07-20 | San Diego State University Research Foundation | Zusammensetzungen zur manipulation der pim-1-aktivität bei herzzellen |
| CN103585643A (zh) | 2009-04-03 | 2014-02-19 | 梅里亚有限公司 | 运载新城疫病毒的禽疫苗 |
| WO2012030720A1 (en) | 2010-08-31 | 2012-03-08 | Merial Limited | Newcastle disease virus vectored herpesvirus vaccines |
| WO2012090073A2 (en) | 2010-12-30 | 2012-07-05 | The Netherlands Cancer Institute | Methods and compositions for predicting chemotherapy sensitivity |
| US20140296248A1 (en) | 2011-04-04 | 2014-10-02 | Stichting het Nederlands Kanker Instiuut-Antoni van Leeuwenhoek ziekenhuis | Methods and compositions for predicting resistance to anticancer treatment |
| AU2012240246A1 (en) | 2011-04-04 | 2013-05-09 | Netherlands Cancer Institute | Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors |
| WO2012145577A1 (en) | 2011-04-20 | 2012-10-26 | Merial Limited | Adjuvanted rabies vaccine with improved viscosity profile |
| AP2013007180A0 (en) | 2011-04-25 | 2013-10-31 | Advanced Bioscience Lab Inc | Truncated HIV envelope proteins (ENV), methods andcompositions related thereto |
| EP2714077B1 (de) | 2011-06-01 | 2018-02-28 | Merial, Inc. | Nadellose verabreichung von prrsv-impfstoffen |
| WO2013093629A2 (en) | 2011-12-20 | 2013-06-27 | Netherlands Cancer Institute | Modular vaccines, methods and compositions related thereto |
| GB201202516D0 (en) | 2012-02-13 | 2012-03-28 | Ucl Business Plc | Materials and methods relating to packaging cell lines |
| WO2013138776A1 (en) | 2012-03-16 | 2013-09-19 | Merial Limited | Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g |
| US10106816B2 (en) * | 2012-12-14 | 2018-10-23 | Case Western Reserve University | Genomic RNA packaging enhancer element |
| EP2968514A1 (de) | 2013-03-12 | 2016-01-20 | Merial, Inc. | Mittels reverser genetik hergestellte impfstoffzusammensetzungen gegen schmallenberg-virus und verfahren zur verwendung davon |
| GB201318804D0 (en) * | 2013-10-24 | 2013-12-11 | Adaptimmune Ltd | Vectors for transgene expression |
| GB201322798D0 (en) | 2013-12-20 | 2014-02-05 | Oxford Biomedica Ltd | Production system |
| WO2016073410A1 (en) | 2014-11-03 | 2016-05-12 | Merial, Inc. | Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus |
| ES3050936T3 (en) | 2015-06-23 | 2025-12-23 | Boehringer Ingelheim Vetmedica Gmbh | Prrsv minor protein-containing recombinant viral vectors and methods of making and use thereof |
| ES2987957T3 (es) | 2015-11-23 | 2024-11-18 | Novartis Ag | Vectores de transferencia lentivirales optimizados y usos de los mismos |
| AU2018235130B2 (en) | 2017-03-15 | 2023-12-07 | Oxford Biomedica (Uk) Limited | Method |
| EP3696272A1 (de) | 2017-12-22 | 2020-08-19 | Oxford BioMedica (UK) Limited | Retroviraler vektor |
| MX2020012295A (es) | 2018-05-15 | 2021-03-31 | Flagship Pioneering Innovations V Inc | Composiciones de fusosoma y usos de estas. |
| WO2020014209A1 (en) | 2018-07-09 | 2020-01-16 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions and uses thereof |
| CA3120082A1 (en) | 2018-11-14 | 2020-05-22 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for cns delivery |
| WO2020102503A2 (en) | 2018-11-14 | 2020-05-22 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for t cell delivery |
| WO2020102485A1 (en) | 2018-11-14 | 2020-05-22 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for hematopoietic stem cell delivery |
| AU2020341454A1 (en) | 2019-09-03 | 2022-03-10 | Sana Biotechnology, Inc. | CD24-associated particles and related methods and uses thereof |
| KR20220097492A (ko) | 2019-11-12 | 2022-07-07 | 옥스포드 바이오메디카(유케이) 리미티드 | 생산 시스템 |
| KR20220119439A (ko) | 2019-12-20 | 2022-08-29 | 인스틸 바이오 유케이 리미티드 | 종양 침윤 림프구를 분리하기 위한 장치 및 방법 및 그것의 용도 |
| JP2023513303A (ja) | 2020-02-13 | 2023-03-30 | オックスフォード バイオメディカ（ユーケー）リミテッド | レンチウイルスベクターの製造 |
| DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| US20230118587A1 (en) | 2020-03-13 | 2023-04-20 | Oxford Biomedica (Uk) Limited | Lentiviral Vectors |
| EP4127144A1 (de) | 2020-03-31 | 2023-02-08 | Sana Biotechnology, Inc. | Zielgerichtete lipidpartikel und zusammensetzungen und verwendungen davon |
| WO2021222222A1 (en) | 2020-04-27 | 2021-11-04 | Mccray Jr Paul B | Compositions and methods for the treatment of cystic fibrosis |
| GB202007199D0 (en) | 2020-05-15 | 2020-07-01 | Oxford Biomedica Ltd | Viral vector production |
| US20230190871A1 (en) | 2020-05-20 | 2023-06-22 | Sana Biotechnology, Inc. | Methods and compositions for treatment of viral infections |
| US20230303665A1 (en) | 2020-08-28 | 2023-09-28 | Sana Biotechnology, Inc. | Modified anti-viral binding agents |
| GB202017725D0 (en) | 2020-11-10 | 2020-12-23 | Oxford Biomedica Ltd | Method |
| JP2023554425A (ja) | 2020-12-18 | 2023-12-27 | インスティル バイオ （ユーケイ） リミテッド | 腫瘍浸潤リンパ球の処理 |
| EP4262828A1 (de) | 2020-12-18 | 2023-10-25 | Instil Bio (Uk) Limited | Tumorinfiltrierende lymphozyten und anti-cd47-therapeutika |
| JP2024500748A (ja) | 2020-12-18 | 2024-01-10 | インスティル バイオ （ユーケイ） リミテッド | 腫瘍浸潤リンパ球の処理 |
| CA3204161A1 (en) | 2021-01-11 | 2022-07-14 | Jagesh Vijaykumar SHAH | Use of cd8-targeted viral vectors |
| AU2022244370A1 (en) * | 2021-03-24 | 2023-09-28 | National Resilience, Inc. | Systems and methods for cell-free polypeptide synthesis |
| WO2022251712A1 (en) | 2021-05-28 | 2022-12-01 | Sana Biotechnology, Inc. | Lipid particles containing a truncated baboon endogenous retrovirus (baev) envelope glycoprotein and related methods and uses |
| US20240344083A1 (en) | 2021-08-04 | 2024-10-17 | Sana Biotechnology, Inc. | Use of cd4-targeted viral vectors |
| JPWO2023038055A1 (de) * | 2021-09-08 | 2023-03-16 | ||
| GB202114528D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Lentiviral vectors |
| GB202114534D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Novel viral regulatory elements |
| GB202114532D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Lentiviral Vectors |
| GB202114529D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Lentiviral vectors |
| GB202114530D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Retroviral vectors |
| US20250230511A1 (en) | 2021-10-29 | 2025-07-17 | Sana Biotechnology, Inc. | Methods and reagents for amplifying viral vector nucleic acid products |
| GB202117844D0 (en) | 2021-12-09 | 2022-01-26 | Oxford Biomedica Ltd | Purification method |
| WO2023114949A1 (en) | 2021-12-16 | 2023-06-22 | Sana Biotechnology, Inc. | Methods and systems of particle production |
| US20250059239A1 (en) | 2021-12-17 | 2025-02-20 | Sana Biotechnology, Inc. | Modified paramyxoviridae fusion glycoproteins |
| WO2023115041A1 (en) | 2021-12-17 | 2023-06-22 | Sana Biotechnology, Inc. | Modified paramyxoviridae attachment glycoproteins |
| WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| EP4472646A1 (de) | 2022-02-01 | 2024-12-11 | Sana Biotechnology, Inc. | Auf cd3 abzielende lentivirale vektoren und verwendungen davon |
| WO2023150647A1 (en) | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
| US20250222027A1 (en) | 2022-04-01 | 2025-07-10 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| US20260027145A1 (en) | 2022-07-27 | 2026-01-29 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| GB202211935D0 (en) | 2022-08-16 | 2022-09-28 | Oxford Biomedica Ltd | envelope proteins |
| US20260055146A1 (en) | 2022-08-24 | 2026-02-26 | Sana Biotechnology, Inc. | Delivery of heterologous proteins |
| WO2024064838A1 (en) | 2022-09-21 | 2024-03-28 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
| WO2024081820A1 (en) | 2022-10-13 | 2024-04-18 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
| AU2023375633A1 (en) * | 2022-11-11 | 2025-05-29 | Rnaissance Ag Llc | Fermentation based method for double stranded rna production |
| WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| WO2024220574A1 (en) | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Universal protein g fusogens and adapter systems thereof and related lipid particles and uses |
| WO2024220597A2 (en) | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Digital droplet based assay for detecting replication competent lentiviral vector |
| WO2024220560A1 (en) | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Engineered protein g fusogens and related lipid particles and methods thereof |
| AU2024274792A1 (en) | 2023-05-23 | 2025-10-23 | Sana Biotechnology, Inc. | Tandem fusogens and related lipid particles |
| WO2024259299A1 (en) | 2023-06-14 | 2024-12-19 | The Broad Institute, Inc. | Compositions and methods for identification of vhh antibodies that bind a target antigen |
| WO2025184529A1 (en) | 2024-03-01 | 2025-09-04 | Sana Biotechnology, Inc. | Viral particles with fusogen display and related compositions and methods |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5631154A (en) * | 1988-06-10 | 1997-05-20 | Therion Biologics, Incorporated | Self assembled, defective, non-self-propagating lentivirus particles |
| US5747324A (en) * | 1988-06-10 | 1998-05-05 | Therion Biologics Corporation | Self-assembled, defective, non-self-propagating lentivirus particles |
| JP3247972B2 (ja) * | 1990-05-28 | 2002-01-21 | 財団法人阪大微生物病研究会 | レトロウイルス遺伝子の多量発現能と翻訳後のプロセッシング能とを兼備するプラスミドの作製法、及びこれより得られるプラスミドとその発現産物 |
| WO1991019798A1 (en) | 1990-06-20 | 1991-12-26 | Dana Farber Cancer Institute | Vectors containing hiv packaging sequences, packaging defective hiv vectors, and uses thereof |
| US5981276A (en) * | 1990-06-20 | 1999-11-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
| WO1992021750A1 (en) | 1991-05-29 | 1992-12-10 | THE UNITED STATES OF AMERICA, represented by THE SCRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES | Eukaryotic expression vectors with regulation of rna processing |
| DE69430646T2 (de) | 1993-02-17 | 2003-01-02 | Wisconsin Alumni Research Foundation, Madison | Retroviren vom Typ "more-complex", die LTR von gemischtem Typ enthalten und deren Anwendungen |
| JP4303315B2 (ja) * | 1994-05-09 | 2009-07-29 | オックスフォード バイオメディカ（ユーケー）リミテッド | 非交差性レトロウイルスベクター |
| AU2419595A (en) | 1994-05-10 | 1995-11-29 | Hisamitsu Pharmaceutical Co., Inc. | Recombinant human immunodeficiency virus vector and process for producing the same |
| RU2199585C2 (ru) * | 1994-09-02 | 2003-02-27 | ГСФ-Форшунгсцентрум фюр Умвельт унд Гезундхайт ГмбХ | Ретровирусная векторная конструкция, подвергающаяся промоторной конверсии, способ введения гомологичных или гетерологичных нуклеотидных последовательностей в человеческие или животные клетки in vitro и/или in vivo, рекомбинантная ретровирусная частица, фармацевтическая композиция для генной терапии |
| US6300118B1 (en) * | 1995-06-07 | 2001-10-09 | American Home Products Corporation | Plasmids comprising a genetically altered feline immunodeficiency virus genome |
| US6013516A (en) * | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US6033672A (en) * | 1996-03-15 | 2000-03-07 | University Of Southern California | Method of stimulating an immune response to caprine arthritis-encephalitis virus (CAEV) in humans through the administration of CAEV immunogens |
| GB2325003B (en) * | 1996-10-17 | 2000-05-10 | Oxford Biomedica Ltd | Rectroviral vectors |
| WO1998039463A2 (en) * | 1997-03-06 | 1998-09-11 | Ueberla Klaus | Lentivirus based vector and vector system |
| US6207455B1 (en) * | 1997-05-01 | 2001-03-27 | Lung-Ji Chang | Lentiviral vectors |
| EP0981636B1 (de) * | 1997-05-13 | 2005-03-23 | University Of North Carolina At Chapel Hill | Auf lentivirus basierende gentransfer-vektoren |
| GB9720465D0 (en) * | 1997-09-25 | 1997-11-26 | Oxford Biomedica Ltd | Dual-virus vectors |
| CA2304983A1 (en) * | 1997-09-24 | 1999-04-01 | The Regents Of The University Of California | Non-primate lentiviral vectors and packaging systems |
| US5994136A (en) * | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| ATE528405T1 (de) * | 1997-12-22 | 2011-10-15 | Oxford Biomedica Ltd | Auf dem virus der infektiösen pferdeanämie (eiav) basierende vektoren |
-
1998
- 1998-12-22 AT AT07015653T patent/ATE528405T1/de active
- 1998-12-22 DK DK07015653.4T patent/DK1895010T3/da active
- 1998-12-22 CN CNB988137666A patent/CN1322137C/zh not_active Expired - Lifetime
- 1998-12-22 AU AU17732/99A patent/AU760287B2/en not_active Expired
- 1998-12-22 EP EP07015653A patent/EP1895010B1/de not_active Expired - Lifetime
- 1998-12-22 EP EP98962602A patent/EP1042493A1/de not_active Withdrawn
- 1998-12-22 PT PT07015653T patent/PT1895010E/pt unknown
- 1998-12-22 ES ES07015653T patent/ES2373406T3/es not_active Expired - Lifetime
- 1998-12-22 CA CA002315269A patent/CA2315269A1/en not_active Abandoned
- 1998-12-22 WO PCT/GB1998/003876 patent/WO1999032646A1/en not_active Ceased
- 1998-12-22 JP JP2000525564A patent/JP4578678B2/ja not_active Expired - Lifetime
-
1999
- 1999-01-27 US US09/238,356 patent/US6312683B1/en not_active Expired - Lifetime
-
2001
- 2001-05-29 US US09/867,947 patent/US20030147907A1/en not_active Abandoned
-
2005
- 2005-06-15 US US11/154,421 patent/US20060024274A1/en not_active Abandoned
-
2011
- 2011-12-12 CY CY20111101230T patent/CY1112196T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1285000A (zh) | 2001-02-21 |
| ES2373406T3 (es) | 2012-02-03 |
| CA2315269A1 (en) | 1999-07-01 |
| AU1773299A (en) | 1999-07-12 |
| EP1895010B1 (de) | 2011-10-12 |
| CN1322137C (zh) | 2007-06-20 |
| EP1042493A1 (de) | 2000-10-11 |
| JP2002516065A (ja) | 2002-06-04 |
| PT1895010E (pt) | 2012-01-25 |
| EP1895010A3 (de) | 2008-04-16 |
| US20060024274A1 (en) | 2006-02-02 |
| DK1895010T3 (da) | 2011-11-21 |
| US6312683B1 (en) | 2001-11-06 |
| CY1112196T1 (el) | 2015-12-09 |
| JP4578678B2 (ja) | 2010-11-10 |
| US20030147907A1 (en) | 2003-08-07 |
| EP1895010A2 (de) | 2008-03-05 |
| AU760287B2 (en) | 2003-05-08 |
| WO1999032646A1 (en) | 1999-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1895010T3 (da) | Vektorer baseret på virus for infektiøs hesteanæmi (eiav) | |
| CY1112985T1 (el) | Χρηση αλληλουχιων dνα τριπλου ελικα για τη μεταφορα νουκλεοτιδικων αλληλουχιων | |
| ATE358732T1 (de) | Anti-virale vektoren | |
| DE69619514D1 (de) | Retrovirale vektoren | |
| PT783321E (pt) | Sequencia nucleotidica viral vr-2332 e metodos de utilizacao | |
| EE9900581A (xx) | LAG-3 pleissimisteisendid | |
| DK1167542T3 (da) | Probe til diagnosticering af infektionssygdom, der opstår fra Enterococcus faecalis | |
| ATE541933T1 (de) | Antigene polypeptide, die mit multipler sklerose assoziiert sind, und verwendungszwecke | |
| NO980212D0 (no) | Primere påvisning av HIV-1 | |
| DE60028066D1 (de) | Lentivirale vektoren für die herstellung von immunotherapeutischen zusammensetzungen | |
| ES2143475T3 (es) | Genes de polifenol oxidasa. | |
| DE69625356D1 (de) | cDNA KLON FÜR DEN SÜDAFRIKANISCHEN ARBOVIRUS NO.86 | |
| ATE142702T1 (de) | Spezifischer nachweis von mycobacterium tuberculosis | |
| ATE452193T1 (de) | Xenobiotische induzierung der genexpression von zytochrom p450 cyp3a4 | |
| DK0431128T3 (da) | Vektor, der koder for selvsamlende, defekte, ikke-selvopformerende viruspartikler | |
| EP0753062A4 (de) | Ribozyme welche auf die retroviralen verpackungssequenzen von expressionsprodukten zielen und rekombinante retroviren solche konstrukte enthaltend | |
| AU5120796A (en) | DNA fragment, recombination vector containing the same and method for expressing foreign genes using the same | |
| BR8506990A (pt) | Vetores de clonagem ou de expressao comportando o genoma do virus de eritroblastose aviaria e celulas transfectadas por estes vetores | |
| ZA941326B (en) | Polyribozyme capable of conferring viral resistance to plants, and resistant plants producing said ribozyme. | |
| DK631387A (da) | Virusvektor | |
| ATE368117T1 (de) | Komplette gensequenz des esel-leukozyten- impfstoffstammes des equinen infektiösen anemievirus und ihre anwendung | |
| FR2680797B1 (de) | ||
| ATE180015T1 (de) | N-carbamoylsarcosin-amidohydrolase, kloniert |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1895010 Country of ref document: EP |